|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
UICC International Union Against Cancer, .
TNM Classification of Malignant Tumours. 8th ed. Wiley Blackwell;
2016
|
|
3
|
WHO Classification of Tumours Editorial
Board, . Thoracic Tumours. WHO Classification of Tumours; 5th
Edition. 2021
|
|
4
|
Attili I, Corvaja C, Spitaleri G, Del
Signore E, Trillo Aliaga P, Passaro A and de Marinis F: New
generations of tyrosine kinase inhibitors in treating NSCLC with
oncogene addiction: Strengths and limitations. Cancers (Basel).
15:50792023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Felip E, Altorki N, Zhou C, Csőszi T,
Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A,
Kenmotsu H, et al: Adjuvant atezolizumab after adjuvant
chemotherapy in resected stage IB-IIIA non-small-cell lung cancer
(IMpower010): A randomised, multicentre, open-label, phase 3 trial.
Lancet. 398:1344–1357. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Forde PM, Spicer J, Lu S, Provencio M,
Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson
SJ, et al: Neoadjuvant Nivolumab plus Chemotherapy in Resectable
Lung Cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heymach JV, Harpole D, Mitsudomi T, Taube
JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, et
al: Perioperative durvalumab for resectable Non-Small-cell lung
cancer. N Engl J Med. 389:1672–1684. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu S, Wu L, Zhang W, Zhang P, Wang W, Fang
W, Xing W, Chen Q, Mei J, Yang L, et al: Perioperative toripalimab
+ platinum-doublet chemotherapy vs. chemotherapy in resectable
stage II/III non-small cell lung cancer (NSCLC): Interim event-free
survival (EFS) analysis of the phase III Neotorch study. J Clin
Oncol. 41:4251262023. View Article : Google Scholar
|
|
9
|
Altorki N, Wang X, Kozono D, Watt C,
Landrenau R, Wigle D, Port J, Jones DR, Conti M, Ashrafi AS, et al:
Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell
Lung Cancer. N Engl J Med. 388:489–498. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saji H, Okada M, Tsuboi M, Nakajima R,
Suzuki K, Aokage K, Aoki T, Okami J, Yoshino I, Ito H, et al:
Segmentectomy versus lobectomy in small-sized peripheral
non-small-cell lung cancer (JCOG0802/WJOG4607L): A multicentre,
open-label, phase 3, randomised, controlled, non-inferiority trial.
Lancet. 399:1607–1617. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aokage K, Suzuki K, Saji H, Wakabayashi M,
Kataoka T, Sekino Y, Fukuda H, Endo M, Hattori A, Mimae T, et al:
Segmentectomy for ground-glass-dominant lung cancer with a tumour
diameter of 3 cm or less including ground-glass opacity (JCOG1211):
A multicentre, single-arm, confirmatory, phase 3 trial. Lancet
Respir Med. 11:540–549. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Offin M, Chan JM, Tenet M, Rizvi HA, Shen
R, Riely GJ, Rekhtman N, Daneshbod Y, Quintanal-Villalonga A,
Penson A, et al: Concurrent RB1 and TP53 alterations define a
subset of EGFR-Mutant lung cancers at risk for histologic
transformation and inferior clinical outcomes. J Thorac Oncol.
14:1784–1793. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Farooq H, Bien H, Chang V, Becker D, Park
YH and Bates SE: Loss of function STK11 alterations and poor
outcomes in non-small-cell lung cancer: Literature and case series
of US Veterans. Semin Oncol. 49:319–325. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moreira AL, Ocampo PSS, Xia Y, Zhong H,
Russell PA, Minami Y, Cooper WA, Yoshida A, Bubendorf L, Papotti M,
et al: A grading system for invasive pulmonary adenocarcinoma: A
proposal from the international association for the study of lung
cancer pathology committee. J Thorac Oncol. 15:1599–1610. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Varga Z, Sinn P and Seidman AD: Summary of
head-to-head comparisons of patient risk classifications by the
21-gene Recurrence Score® (RS) assay and other genomic
assays for early breast cancer. Int J Cancer. 145:882–893. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seldin DC and Leder P: Casein Kinase II α
Transgene-Induced murine lymphoma: Relation to theileriosis in
cattle. Science. 267:894–897. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fleuren EDG, Zhang L, Wu J and Daly RJ:
The kinome ‘at large’ in cancer. Nat Rev Cancer. 16:83–98. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chua MMJ, Lee M and Dominguez I:
Cancer-type dependent expression of CK2 transcripts. PLoS One.
12:e01888542017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Strum SW, Gyenis L and Litchfield DW:
CSNK2 in cancer: Pathophysiology and translational applications. Br
J Cancer. 126:994–1003. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gapany M, Faust RA, Tawfic S, Davis A,
Adams GL, Leder P and Ahmed K: Association of elevated protein
kinase CK2 activity with aggressive behavior of squamous cell
carcinoma of the head and neck. Mol Med. 1:659–666. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Landesman-Bollag E, Romieu-Mourez R, Song
DH, Sonenshein GE, Cardiff RD and Seldin DC: Protein kinase CK2 in
mammary gland tumorigenesis. Oncogene. 20:3247–3257. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Firnau MB and Brieger A: CK2 and the
hallmarks of cancer. Biomedicines. 10:19872022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Homma MK, Shibata T, Suzuki T, Ogura M,
Kozuka-Hata H, Oyama M and Homma Y: Role for protein kinase CK2 on
cell proliferation: Assessing CK2 complex components in the nucleus
during the cell cycle progression. In Protein Kinase CK2 Cellular
Function in Normal and Disease States. Ahmed K, Issinger OG and
Szyszka R: Springer International Publishing; Cham: pp. 197–226.
2015, View Article : Google Scholar
|
|
24
|
Homma MK, Nakato R, Niida A, Bando M,
Fujiki K, Yokota N, Yamamoto S, Shibata T, Takagi M, Yamaki J, et
al: Cell cycle-dependent gene networks for cell proliferation
activated by nuclear CK2α complexes. Life Sci Alliance.
7:e2023020772023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Homma MK, Kiko Y, Hashimoto Y, Nagatsuka
M, Katagata N, Masui S, Homma Y and Nomizu T: Intracellular
localization of CK2α as a prognostic factor in invasive breast
carcinomas. Cancer Sci. 112:619–628. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Korsensky L, Chorev D, Saleem H,
Heller-Japheth R, Rabinovitz S, Haif S, Dahan N, Ziv T and Ron D:
Regulation of stability and inhibitory activity of the tumor
suppressor SEF through casein-kinase II-mediated phosphorylation.
Cell Signal. 86:1100852021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sit M, Aktas G, Ozer B, Kocak MZ, Erkus E,
Erkol H, Yaman S and Savli H: Mean platelet volume: An overlooked
herald of malignant thyroid nodules. Acta Clin Croat. 58:417–420.
2019.PubMed/NCBI
|
|
28
|
Atak BM, Bakir Kahveci G, Bilgin S,
Kurtkulagi O and Kosekli MA: Platelet to lymphocyte ratio in
differentiation of benign and malignant thyroid nodules. Exp Biomed
Res. 4:148–153. 2021. View Article : Google Scholar
|
|
29
|
Hong H and Benveniste EN: The immune
regulatory role of protein kinase CK2 and its implications for
treatment of cancer. Biomedicines. 9:19322021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Di Maira G, Salvi M, Arrigoni G, Marin O,
Sarno S, Brustolon F, Pinna LA and Ruzzene M: Protein kinase CK2
phosphorylates and upregulates Akt/PKB. Cell Death Differ.
12:668–677. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Di Maira G, Brustolon F, Pinna LA and
Ruzzene M: Dephosphorylation and inactivation of Akt/PKB is
counteracted by protein kinase CK2 in HEK 293T cells. Cell Mol Life
Sci. 66:3363–3373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang D, Westerheide SD, Hanson JL and
Baldwin AS Jr: Tumor necrosis factor alpha-induced phosphorylation
of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol
Chem. 275:32592–32597. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liongue C, O'Sullivan LA, Trengove MC and
Ward AC: Evolution of JAK-STAT pathway components: Mechanisms and
role in immune system development. PLoS One. 7:e327772012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Manni S, Brancalion A, Mandato E, Tubi LQ,
Colpo A, Pizzi M, Cappellesso R, Zaffino F, Di Maggio SA, et al:
Protein kinase CK2 inhibition down modulates the NF-κB and STAT3
survival pathways, enhances the cellular proteotoxic stress and
synergistically boosts the cytotoxic effect of bortezomib on
multiple myeloma and mantle cell lymphoma cells. PLoS One.
8:e752802013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zheng Y, Qin H, Frank SJ, Deng L,
Litchfield DW, Tefferi A, Pardanani A, Lin FT, Li J, Sha B and
Benveniste EN: A CK2-dependent mechanism for activation of the
JAK-STAT signaling pathway. Blood. 118:156–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hashimoto A, Gao C, Mastio J, Kossenkov A,
Abrams SI, Purandare AV, Desilva H, Wee S, Hunt J, Jure-Kunkel M
and Gabrilovich DI: Inhibition of casein kinase 2 disrupts
differentiation of myeloid cells in cancer and enhances the
efficacy of immunotherapy in Mice. Cancer Res. 78:5644–5655. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu R, Tang W, Qiu K, Li P, Li Y, Li D and
He Z: An Integrative Pan-cancer analysis of the prognostic and
immunological role of casein kinase 2 alpha Protein 1 (CSNK2A1) in
human cancers: A study based on bioinformatics and
immunohistochemical analysis. Int J Gen Med. 14:6215–6232. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
American Joint Committee on Cancer, . AJCC
Cancer Staging Manual. 8th edition. Springer; 2017
|
|
39
|
Seto T, Kiura K, Nishio M, Nakagawa K,
Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, et
al: CH5424802 (RO5424802) for patients with ALK-rearranged advanced
non-small-cell lung cancer (AF-001JP study): A single-arm,
open-label, phase 1–2 study. Lancet Oncol. 14:590–598. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Roach C, Zhang N, Corigliano E, Jansson M,
Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D and
Kulangara K: Development of a companion diagnostic PD-L1
immunohistochemistry assay for pembrolizumab therapy in
non-small-cell lung cancer. Appl Immunohistochem Mol Morphol.
24:392–397. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jänne PA, Yang JCH, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Terata K, Saito H, Nanjo H, Hiroshima Y,
Ito S, Narita K, Akagami Y, Nakamura R, Konno H, Ito A, et al:
Novel rapid-immunohistochemistry using an alternating current
electric field for intraoperative diagnosis of sentinel lymph nodes
in breast cancer. Sci Rep. 7:28102017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sotiriou C and Pusztai L: Gene-expression
signatures in breast cancer. N Engl J Med. 360:790–800. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Harris LN, Ismaila N, McShane LM, Andre F,
Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC,
Mennel RG, et al: Use of biomarkers to guide decisions on adjuvant
systemic therapy for women with early-stage invasive breast cancer:
American Society of Clinical Oncology clinical practice guideline.
J Clin Oncol. 34:1134–1150. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Giuliano AE, Connolly JL, Edge SB,
Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ and
Hortobagyi GN: Breast Cancer-Major changes in the American Joint
Committee on Cancer eighth edition cancer staging manual. CA Cancer
J Clin. 67:290–303. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu Y, Amin EB, Mayo MW, Chudgar NP,
Bucciarelli PR, Kadota K, Adusumilli PS and Jones DR: CK2α, drives
lung cancer metastasis by targeting brms1 nuclear export and
degradation. Cancer Res. 76:2675–2686. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang B, Yao J, Li B, Shao G and Cui Y:
Inhibition of protein kinase CK2 sensitizes non-small cell lung
cancer cells to cisplatin via upregulation of PML. Mol Cell
Biochem. 436:87–97. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
So KS, Rho JK, Choi YJ, Kim SY, Choi CM,
Chun YJ and Lee JC: AKT/mTOR down-regulation by CX-4945, a CK2
inhibitor, promotes apoptosis in chemorefractory non-small cell
lung cancer cells. Anticancer Res. 35:1537–1542. 2015.PubMed/NCBI
|
|
49
|
Jin C, Song P and Pang J: The CK2
inhibitor CX4945 reverses cisplatin resistance in the A549/DDP
human lung adenocarcinoma cell line. Oncol Lett. 18:3845–3856.
2019.PubMed/NCBI
|
|
50
|
Zhao X, Wei Y, Chu YY, Li Y, Hsu JM, Jiang
Z, Liu C, Hsu JL, Chang WC, Yang R, et al: Phosphorylation and
stabilization of PD-L1 by CK2 suppresses dendritic cell function.
Cancer Res. 82:2185–2195. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Husain K, Williamson TT, Nelson N and
Ghansah T: Protein kinase 2 (CK2): A potential regulator of immune
cell development and function in cancer. Immunol Med. 44:159–174.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jang DE, Song J, Park JW, Yoon SH and Bae
YS: Protein kinase CK2 activates Nrf2 via autophagic degradation of
Keap1 and activation of AMPK in human cancer cells. BMB Rep.
53:72–277. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hellyer JA, Padda SK, Diehn M and Wakelee
HA: Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. J
Thorac Oncol. 16:395–403. 2021. View Article : Google Scholar : PubMed/NCBI
|
